Guanethidine sulphate was synthesized in 1959. Guanethidine is thought to lowing blood pressure
by interfering with the metabolism of chemical transmitter substances in post-ganglionic sympathetic nerve fibres.
Ablation of sympathetic fibers is associated with a loss of rat endothelial cell marker (RECA), but no significant effect of guanethidine was found on the survival of endothelial cells and mesenchymal stem cells in vitro[1].
.
Guanethidine (30 mg/kg, s.c., 1 h) unaffected IL-18 hypernociception in TNFR1(-/-) mice as a sympathetic blocker[2].
.
| Animal Model: | Wild-type (WT) Balb/c,TNFR1(-/-)and IFN-γ-γ(-/-) mice[2]. |
| Dosage: | 30 mg/kg |
| Administration: | Guanethidine (30 mg/kg, s.c., 1 h, diluted in saline) |
| Result: | Pre-treatment with guanethidine (sympathetic blocker) unaffected IL-18 hypernociception in TNFR1(-/-) mice. |